Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.
Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.
A holder of RYTM common stock filed a notice to sell up to 5,079 shares through Morgan Stanley Smith Barney LLC on or after 08/13/2026 on NASDAQ. The shares relate to an exercise of stock options from 2024 and restricted stock units dated 02/01/2025, with an aggregate market value of $597,290.40.
RYTM filed a notice of proposed sale of common stock, to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ. The securities information section lists 75,834 shares, including 56,601 shares tied to an Exercise of Stock Options dated August 13, 2026, and 19,233 shares related to Restricted Stock Units dated February 11, 2024.
Rhythm Pharmaceuticals has a planned sale of 57,000 shares of its common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on August 12, 2026. The shares have an aggregate market value of $6,432,165.00 and are listed on NASDAQ. The sale includes 46,625 shares issuable from the exercise of stock options dated August 12, 2026, and 10,375 shares from restricted stock units dated April 14, 2024.
Rhythm Pharmaceuticals insider Pamela Cramer filed a Form 144 indicating planned sales of company common stock through Morgan Stanley Smith Barney LLC. The filing lists 10b5-1 plan sales and includes shares issuable from stock option exercises and restricted stock units, as well as a prior sale of 3,520 shares for $411,452.80 on August 10, 2026.
Rhythm Pharmaceuticals, Inc. reported total revenues of $71.3 million for the quarter ended June 30 2026, all from IMCIVREE product sales, up from $48.5 million a year earlier. U.S. net product revenue was $51.0 million and international revenue was $20.3 million.
The company recorded a quarterly net loss of $49.3 million and a basic and diluted net loss per share of $0.73, with an accumulated deficit of $1.46 billion. As of June 30 2026, cash, cash equivalents and short‑term investments totaled $330.9 million, against a deferred royalty obligation of $106.1 million and Series A convertible preferred stock carrying value of $114.3 million. Management believes existing cash resources will be sufficient to fund operations for at least the next 24 months while it continues commercial expansion and development of its MC4R‑pathway pipeline.
Rhythm Pharmaceuticals, Inc. reported second‑quarter 2026 results highlighted by uptake of IMCIVREE for acquired hypothalamic obesity. Net product revenue from global IMCIVREE sales was $71.3 million, a 19% sequential increase, with U.S. revenue of $51.0 million (72% of the total) and ex‑U.S. revenue of $20.3 million, which included a $3.8 million French Contribution M charge. Net loss attributable to common stockholders was $(50.4) million, or $(0.73) per share. Cash, cash equivalents and short‑term investments were $330.9 million as of June 30, 2026, which the company expects will fund operations for at least 24 months.
Since FDA approval in March 2026, the acquired HO launch generated more than 400 patient start forms from approximately 300 prescribers and increased reimbursed patients by greater than 20% quarter over quarter. Preliminary Phase 2 data for weekly injectable RM‑718 in acquired HO showed a −11.6% mean BMI reduction at 16 weeks (n=7), comparable to prior results with setmelanotide and bivamelagon, with only mild, localized hyperpigmentation noted. Rhythm reiterated 2026 Non‑GAAP operating expense guidance of $363–$397 million and outlined milestones including a Japan IMCIVREE HO launch decision by year‑end 2026, European launches beginning in 2027, and initiation of a pivotal Phase 3 bivamelagon trial.
Rhythm Pharmaceuticals Chief Scientific Officer Alastair Garfield reported routine equity compensation activity involving restricted stock units and related tax withholding. On July 1, 2026, he exercised 4,445 restricted stock units, each converting into one share of common stock, increasing his direct common stock holdings to 12,208 shares.
To cover withholding taxes on this vesting, 2,150 common shares were withheld, classified as a tax-withholding disposition rather than an open-market sale. Following these transactions, Garfield also holds 8,888 restricted stock units, which vest in four equal annual installments of 25% each starting from July 1, 2024, contingent on his continued service.
RHYTHM PHARMACEUTICALS director Jean Christophe reported equity awards and an RSU conversion into common stock. He received 2,324 restricted stock units, each representing one share of common stock, which fully vest upon the earlier of June 24, 2027 or the day before the 2027 annual meeting, subject to continued service.
He also received stock options for 3,691 shares of common stock at an exercise price of $107.55 per share, vesting on the same schedule and expiring on June 23, 2036. In addition, 4,712 previously granted restricted stock units were exercised and converted into 4,712 shares of common stock, leaving no remaining units from that grant. Following these transactions, he holds 11,712 shares of common stock directly.